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Abstract
Background—Cancer is one of the top five most costly diseases in the United States and leads 
to substantial work loss. Nevertheless, limited state-level estimates of cancer absenteeism costs 
have been published.
Methods—In analyses of data from the 2004–2008 Medical Expenditure Panel Survey, the 2004 
National Nursing Home Survey, the U.S. Census Bureau for 2008, and the 2009 Current 
Population Survey, we used regression modeling to estimate annual state-level absenteeism costs 
attributable to cancer from 2004 to 2008.
Results—We estimated that the state-level median number of days of absenteeism per year 
among employed cancer patients was 6.1 days and that annual state-level cancer absenteeism costs 
ranged from $14.9 million to $915.9 million (median = $115.9 million) across states in 2010 
dollars. Absenteeism costs are approximately 6.5% of the costs of premature cancer mortality.
Conclusions—The results from this study suggest that lost productivity attributable to cancer is 
a substantial cost to employees and employers and contributes to estimates of the overall impact of 
cancer in a state population.
Cancer is one of the top five most costly diseases in the United States.1 For example, in 
2007, the total direct cost of cancer treatment in the United States was estimated to be 
$103.8 billion, and the cost of lost productivity from premature deaths attributed to cancer 
was estimated to be $123.0 billion,2 and is projected to increase to $147.6 billion by 2020.3 
In addition, cancer generates lost productivity costs associated with missed work among 
employed cancer patients (ie, absenteeism).4–9 Of all US residents in whom cancer was 
diagnosed from 2005 through 2009, 46.8% were younger than 65 years at the time of 
diagnosis.10 Nevertheless, despite published evidence of the large direct and indirect 
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(premature mortality, absenteeism) economic costs associated with cancer at the national 
level and evidence of direct costs at the state level,11,12 to our knowledge there has not been 
an analysis of state-level cancer absenteeism costs.
To fully understand the total economic cost of cancer to society, it is important to know the 
value of missed workdays among employed cancer patients. Thus, the purpose of this study 
is to estimate annual state-level costs of cancer-related absenteeism. Our costs were 
estimated as the value of lost productivity to employees and employers that could be averted 
if cancer were prevented. To our knowledge, this is the first study to examine the 
productivity loss attributable to missed workdays among cancer patients at the state level.
METHODS
Overview
We estimated state-level cancer absenteeism costs in two steps. First, we estimated the 
“treated cancer prevalence rate” (ie, the percentage of a state’s residents who had been 
treated for cancer within the previous year) and the average number of cancer-attributable 
days of absenteeism per person treated in the previous year, by age group (18 to 44, 45 to 
64, or ≥65 years) and sex (male or female). Second, we estimated the total state-level costs 
of cancer-attributable absenteeism for each age/sex group by multiplying the state 
population by the treated cancer prevalence rate, the percentage of cancer patients who were 
employed, the average duration of cancer-related absenteeism, and the average wages for 
each age/sex group, and then adding the costs for all age/sex groups.
Estimates of the Percentage of State’s Residents Treated for Cancer
To estimate the average annual percentage of state’s residents who had been treated for 
cancer from 2004 through 2008, we used data from the “Medical Condition files” of the 
2004–2008 Medical Expenditure Panel Survey (MEPS),13 a nationally representative survey 
of the civilian noninstitutionalized population administered by the Agency for Healthcare 
Research and Quality. MEPS respondents self-reported their conditions, or those of 
household members, and these reported conditions were then assigned codes from the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), 
and grouped into clinically meaningful categories using Clinical Classification Codes.14 
Cancer was defined using ICD-9-CM codes on the basis of any diagnosis of cancer 
(including nonmelanoma skin cancer), either at admission or at the time of the survey and 
primary or secondary diagnosis. We define persons treated for cancer as individuals with a 
medical event with Clinical Classification Codes of 11 through 43 and 45 during the 
interview year. This definition includes both new and existing cancers.
Because sample sizes were too small to estimate the percentage of MEPS respondents 
treated for cancer directly by age, sex, and region, we used logistic regression models to 
estimate the percentage of MEPS respondents treated for cancer. The logistic regression 
models were adjusted for survey year and survey participants’ age, sex, and region of 
residence (ie, Northeast, South, Midwest, or West). Preliminary stepwise regressions were 
performed to identify statistically significant age-by-sex-by-region interactions (at α = 0.05) 
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for which there was sufficient sample size and power to detect differences in treated cancer 
prevalence. The nationally representative average treated population prevalence for 2004 to 
2008 was predicted from the final, survey-weighted logistic regressions for each age, sex, 
and region combination. These estimates reflected additional adjustments accounting for 
cancer prevalence among nursing home residents using data from the 2004 National Nursing 
Home Survey (NNHS) and the same ICD-9-CM codes as in MEPS.15 For each age and sex 
group, the treated population prevalence from MEPS was scaled by the ratio of the number 
of people with cancer in MEPS and the NNHS to the number of people with cancer in 
MEPS alone. These methods have been used in earlier studies of state-level direct costs of 
cancer.11,12
Estimates of Cancer-Attributable Absenteeism
We used a negative binomial regression model to estimate the average annual number of 
days of work missed because of illness among participants in the 2004–2008 MEPS. 
Negative binomial models, an extension of Poisson models, are used when the dependent 
variable is a count (ie, a nonnegative integer). The model for workdays missed was 
estimated for the adult working population from the MEPS. The dependent variable was the 
annual number of workdays missed because of illness or injury from the Household 
Component survey. All regressions were adjusted for the following variables (n = 59,368): 
age; age squared; sex; race/ethnicity (white non-Hispanic [reference], black, white Hispanic, 
and other race/ethnicity); education (missing, less than high school, high school, college 
degree [reference], graduate degree, other degree, and younger than 16 years); household 
income (<100% of poverty line, 100% to 200% of poverty line, 200% to 400% of poverty 
line [reference], and >400% of poverty line); health insurance status (Medicaid, uninsured, 
private insurance, and other insurance—not mutually exclusive); family size; occupation 
(professional occupations, management/business/finance, sales, clerical, construction/
extraction/maintenance, production/transportation/material moving, service industry, 
farming/fishing/forestry, military, unclassified, and missing occupation [reference]); survey 
year; and indicator variables for cancer, arthritis, asthma, back problems, congestive heart 
failure, chronic obstructive pulmonary disease, coronary heart disease, depression, diabetes, 
dyslipidemia, HIV/AIDS, hypertension, injuries, other cardiovascular disease, other mental 
health/substance abuse, pneumonia, pregnancies, renal failure, skin disorders, and stroke.
Standard calculations of attributable costs can double-count costs in nonlinear regression 
models with multiple medical conditions.16 One way to avoid double-counting is to use the 
regression model to predict absenteeism for every combination of observed conditions. We 
estimated days of absenteeism attributable to cancer by comparing predicted days of 
absenteeism for people with each unique combination of diseases with predicted days of 
absenteeism for people without that combination of diseases while holding all other 
variables constant. For example, we considered cancer alone and cancer with hypertension 
as two different combinations of diseases. We then divided the total number of days of 
absenteeism attributable to the combinations of diseases back to the constituent diseases (ie, 
a share of all cancer with hypertension disease absenteeism that are attributable to cancer). 
The process attributes a greater share of the absenteeism for the combination of diseases to 
the disease with the larger coefficient in the regression.16 We then estimated average annual 
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per-person days of cancer-attributable absenteeism (excess number of days missed because 
of cancer) for each age/sex/region category on the basis of coefficients from the national 
model.
Population, Employment, and Wage Estimates
Our estimates of total state populations and state populations broken down by sex and age 
for 2008 were based on 2008 U.S. Census Bureau estimates.17 To estimate the number of 
people in each age/sex/state category who had been treated for cancer in 2008, we multiplied 
our estimates of the treated cancer prevalence rate for each age/sex category by our 
estimates of the total number of people in the corresponding age/sex/state category.
Our estimates of the percentage of people treated for cancer who were employed, by age and 
sex, were obtained from the 2004–2008 MEPS. Because we adjusted our estimates of treated 
cancer prevalence rates upward to account for cancer cases among nursing home residents, 
we used the 2004 NNHS to include nursing home residents in our count of nonemployed 
patients in the denominator in determining the percentage of cancer patients who were 
employed. Our estimates of average daily earnings by sex/age/state were taken from the 
2009 Current Population Survey; nevertheless, these estimates did not reflect the cancer 
status of survey participants.18
For each age and sex group, we calculated total absenteeism costs attributable to cancer by 
multiplying (1) the total number of people in that group who had been treated for cancer 
(obtained by multiplying the state population by the treated cancer prevalence rate) by (2) 
the percentage of those treated for cancer who were employed by (3) the average annual 
number of workdays missed per employed person because of cancer by (4) the average daily 
earnings of US workers. We then added our estimates of absenteeism costs for state 
residents in each age/sex group to produce our overall estimates of state-level absenteeism 
costs. All cost estimates are expressed as 2010-equivalent dollars using the gross domestic 
product general price index as recommended by the Agency for Healthcare Research and 
Quality to reflect more current dollar values.19
Because of the large number of data sources that we used to produce our estimates, we could 
not generate standard errors for our estimates of cancer-attributable absenteeism costs. 
Nevertheless, because the MEPS was our primary source of data, we were able to generate 
standard errors for our estimates of treated cancer prevalence rates.
RESULTS
Adjusting for personal characteristics, the rate of workdays missed for people with cancer 
was 2.87 (P = 0.00) times higher than for people without cancer (Table 1). Other covariates 
in the regression had the expected impact on absenteeism. The rate of workdays missed were 
higher for people with the included medical conditions, older workers, females, blacks, 
lower education, lower income, and the uninsured.
Our state-level estimates of average annual treated cancer prevalence rates during 2004 to 
2008 ranged from 3.2% in Utah to 5.1% in Florida (median = 4.2%; relative standard error = 
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8%) (Table 2). Estimates of the average annual number of employed residents treated for 
cancer ranged from 9808 in Wyoming to 618,312 in California (median = 78,485). 
Estimates of the average annual number of days of work missed because of cancer per 
employed resident ranged from 5.9 days in Utah to 6.3 days in Ohio (median = 6.1 days) 
(Table 2). Estimates of the total average annual number of days of work missed because of 
cancer during 2004 to 2008 ranged from 59,302 days in Wyoming to 3,726,439 days in 
California (median = 482,730). Estimates of total annual cancer-attributable absenteeism 
costs ranged from $14.9 million in Wyoming to $915.9 million in California (median = 
$115.9 million) in 2010 dollars.
DISCUSSION
Our findings indicated that in the median state, US workers treated for cancer missed an 
average of 6.1 days of work per year because of cancer during 2004 to 2008 and that the 
annual state-level cost of cancer-related absenteeism to employees and employers ranged 
from $14.9 million in Wyoming to $915.9 million in California.
Estimates of cancer treatment costs are important in estimating the total economic costs of 
cancer.12,20–25 Nevertheless, these estimates do not reflect the complete picture of the 
economic burden of cancer because they do not include cancer-related productivity costs 
from sick leave, ineffective presence in the workplace, disability, premature death, and 
intangible costs associated with psychological pain and stress by cancer patients. Results of 
several studies4–9,26,27 have shown substantial absenteeism associated with cancer, and the 
indirect costs of cancer (including absenteeism) has generally been shown to be greater than 
the direct costs of cancer.2 The National Institutes of Health estimated that in 2007 the 
overall cost of cancer in the United States was $226.8 billion: $103.8 billion for direct 
medical costs (all cancer-related health expenditures) and $123.0 billion for indirect costs 
attributable to the lost productivity of workers who die from cancer before the age of 65 
years, which does not include absenteeism among survivors.2 The sum of our state-level 
absenteeism costs equals $8.1 billion or approximately 6.5% of the costs of premature 
cancer mortality.
Hansen et al28 conducted a study to examine whether physical fatigue, depression, anxiety, 
and cognitive limitations were differentially associated with work limitations in breast 
cancer survivors in comparison to a noncancer group of employed workers. Their study 
indicated that cancer survivors reported greater work limitations than a noncancer 
comparison group and that the breast cancer survivor group reported more time off. Hansen 
et al28 examined the individual contributions of symptom burden on work limitations, but 
they did not estimate the number of days missed, nor the dollar value of missed workdays to 
the employer and employee.
Other studies have also shown substantial absenteeism associated with other chronic 
diseases.29–31 Waehrer et al29 estimated and compared costs (including employer 
productivity losses and other indirect costs such as victim productivity losses and 
administrative costs) of occupational injury and illnesses within the health services sector. 
They reported high and variable costs within the health services sector across occupations, 
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industries, sex, race, and types of nonfatal injuries and illnesses. Ozminkowski et al30 
estimated relative medical expenditures, absenteeism costs, and short-term disability benefit 
cost burden of rheumatoid arthritis (RA) for nine major US employers and employees by 
comparing costs for workers with RA versus a matched group of workers who did not have 
RA. They found that employees with RA had higher average absenteeism cost. Carls et al31 
estimated the impact of medication adherence on absenteeism and short-term disability 
among employees with chronic diseases. Their study results indicated that nonadherent 
working patients with chronic diseases realized between 1.7 and 7.1 more days absent from 
work than adherent employees. All these studies confirm the link between chronic diseases 
and missed workdays.
Our estimates of the average number of days per year that employees with cancer were 
absent from work because of their cancer were somewhat lower than previous estimates. For 
example, across all cancer sites, Finkelstein et al7 estimated that individuals undergoing 
active cancer care missed an average of 22.3 more workdays per year than those without 
cancer. Fu et al8 estimated that privately employed women with breast cancer had an 
average of 14 days of absenteeism and 46 days of short-term disability attributable to their 
breast cancer in the first year after diagnosis. There are at least three reasons that our 
estimates of cancer-attributable days of absenteeism tended to be lower than the estimates 
from other studies. First, we minimized potential double-counting of days missed when 
multiple diseases were included in the regression model.16 Second, our estimates of cancer-
related absenteeism were based on all types of cancer combined (including nonmelanoma 
skin cancer) rather than on specific types of cancer. Cancers of specific sites are likely to 
lead to more absenteeism (eg, breast cancer) or less absenteeism (eg, nonmelanoma skin 
cancer) than the average for all types of cancer combined. Had we excluded nonmelanoma 
skin cancer from our analysis, the prevalence estimates could have dropped by about 29% 
(2.6% to 1.8%) and the mean days missed could have increased by about 28% (9.3 to 11.9). 
Third, because we did not have information on MEPS respondents’ timing of diagnosis or 
cancer stage, our absenteeism estimates were the average for all treatment phases and stages. 
Per-person estimates from the MEPS may not fully reflect the high-intensity initial and last 
year of life phases. Nevertheless, different stages are treated with different intensity of 
treatment and modality, leading to differences in absenteeism. Fourth, our estimates are an 
average across all employed persons, both full-time and part-time. We used average daily 
earnings for an entire day’s work, on the basis of average hourly earnings across all 
employed persons (full-time and part-time). The inclusion of part-time workers may have 
lowered estimates of absenteeism and wages relative to studies that only included full-time 
workers.
With almost half of all cancer diagnoses occurring among US residents younger than 65 
years,10 it is clear that cancer-related absenteeism cost has a significant economic impact on 
US employees and employers. Our findings underscore the need for increased investments 
in cancer prevention and control programs. Through prevention and early detection, such 
investments are likely to increase worker productivity and reduce the costs associated with 
worker absenteeism.
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The MEPS, our primary data source, has at least four notable limitations that may have 
affected our estimates: (1) its results are subject to sampling error, which creates uncertainty 
around the estimates; (2) its participants’ reports of their cancer status were not verified by 
chart review; (3) its small sample sizes precluded us from stratifying our estimates of cancer 
costs by type of cancer; and (4) cancer stage is not included in the survey. Our definition of 
treated prevalence was based on treatment in the prior year; as a result, our estimates likely 
represent a higher cost population than estimates that include people who have not sought 
treatment recently.
Moreover, because we generated state estimates from a national model, differences in our 
estimates of state-level absenteeism costs were primarily a reflection of differences in 
population size and the distribution of demographic characteristics rather than differences in 
cancer prevalence or work practices. Although we adjusted state-level estimates of treated 
prevalence rates to account for regional differences in these rates, our results probably 
understate the true differences in state-level work patterns. Our adjustments for regional 
differences used stepwise regression, which is atheoretical when selecting explanatory 
variables for an outcome. We were only interested in identifying the number of dimensions 
among age, sex, and region for which our data would support stratifying treated cancer 
prevalence.
Another limitation to our cost estimates is that they do not reflect the overall indirect costs 
of cancer, which, in addition to the costs of cancer-related absenteeism, include their 
permanent exit from the labor force through retirement or death and their potentially lower 
productivity while at work, as well as costs attributable to time away from work among 
caregivers of cancer patients.
CONCLUSIONS
This study adds to the current literature describing the absenteeism cost related to cancer. 
Our results showed that the median annual state-level cost estimates of cancer-related 
absenteeism were substantial, $115.9 million in 2010 dollars. State-level estimates of 
cancer-attributable absenteeism costs can complement state-level estimates of other cancer 
costs to provide a more comprehensive picture of the financial impact of cancer in a state 
population. Absenteeism from cancer costs states through lost wages, taxes, and output. The 
implications of this work suggest that more work to reduce the morbidity burden of cancer 
could lower the economic burden of cancer substantially. Strategies to reduce cancer 
morbidity include increased primary prevention—through vaccines and risk factor 
modifications, detection of cancers at an early stage when treatments are most likely and less 
costly, and delivery of effective treatments. This study highlights the need for such 
interventions given the high costs of cancer and provides an important baseline for 
understanding the impact of cancer prevention and control efforts on cancer-related 
absenteeism costs at the state level. Decision makers can use the information as a basis to 
compare the costs and benefits of interventions to determine the best way of allocating 
resources among competing priorities.
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• Summarize the new state-level data on missed work days attributable to cancer, 
along with their contribution to the total societal cost of cancer.
• Identify median absence days associated with cancer and related costs, along 
with the extent of variation between states.
• Discuss the study implications for efforts to reduce the burden of morbidity 
associated with cancer
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TABLE 1
Incident Rate Ratios for Workdays Missed From Negative Binomial Regression Using Medical Expenditure 
Panel Survey, 2004 to 2008
Workdays Missed
(n = 59,368)
Variable Incidence Rate Ratio P
Conditions
  Cancer 2.87 0.00
  Hypertension 1.28 0.00
  CHD 2.03 0.00
  Stroke 4.15 0.00
  CHF 1.90 0.03
  Other heart disease 1.45 0.00
  Diabetes 1.50 0.00
  Arthritis 1.94 0.00
  Asthma 1.58 0.00
  Depression 1.89 0.00
  HIV 4.10 0.00
  Cholesterol 1.04 0.51
  Injury 3.56 0.00
  Pneumonia 3.13 0.00
  COPD 1.63 0.00
  Mental health/substance abuse 1.55 0.00
  Pregnancy 9.95 0.00
  Back condition 2.12 0.00
  Skin condition 1.29 0.00
  Renal failure 3.35 0.00
Age
  Age 1.05 0.00
  Age squared 1.00 0.00
Sex
  Male* 1.00 –
  Female 1.25 0.00
Race/ethnicity
  White non-Hispanic* 1.00 –
  Black 1.20 0.00
  White Hispanic 0.93 0.12
  Other race/ethnicity 1.02 0.66
Education
  Missing degree status 1.16 0.50
  Less than high school 1.16 0.03
  High school 1.25 0.00
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Workdays Missed
(n = 59,368)
Variable Incidence Rate Ratio P
  College degree* 1.00 –
  Graduate degree 0.97 0.58
  Other degree 1.15 0.02
Younger than 16 y 1.10 0.65
Household income
  Less than 100% of poverty line 1.27 0.00
  100–200% of poverty line 1.06 0.22
  200–400% of poverty line* 1.00 –
  Greater than 400% of poverty line 0.83 0.00
Insurance†
  Medicaid 0.94 0.59
  Uninsured 1.36 0.01
  Private insurance 1.16 0.17
  Other insurance 0.91 0.32
Family size 0.93 0.00
Occupation
  Professional occupations 1.00 0.94
  Management/business/finance 0.94 0.33
  Sales 0.99 0.85
  Clerical 1.15 0.04
  Construction/extraction/maintenance 1.19 0.01
  Production/transportation/material moving 1.23 0.00
  Service industry occupation 1.07 0.28
  Farming/fishing/forestry 1.01 0.95
  Military 0.45 0.03
  Unclassified 0.81 0.14
  Missing occupation status* 1.00 –
Year
  2004 1.02 0.61
  2005 1.01 0.91
  2006 1.04 0.37
  2007 0.96 0.32





Insurance categories are not mutually exclusive.
CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; 
y, years.
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TABLE 2
State-Level Estimates of Average Annual Treated Cancer Prevalence Rates, Days of Work Missed Because of 















Alabama 4.4 6.2 524,539 126.4
Alaska 3.3 6.0 70,518 17.5
Arizona 4.2 6.0 666,176 165.2
Arkansas 4.5 6.1 316,197 76.5
California 3.8 6.0 3,726,439 915.9
Colorado 3.8 6.0 522,825 129.1
Connecticut 4.5 6.1 450,845 109.0
Delaware 4.5 6.2 99,415 24.0
District of Columbia 4.1 6.1 64,602 15.1
Florida 5.1 6.2 2,108,964 513.5
Georgia 3.7 6.1 1,016,925 242.6
Hawaii 4.5 6.1 141,147 35.1
Idaho 4.0 6.0 157,395 39.2
Illinois 3.7 6.2 1,328,230 310.8
Indiana 3.8 6.3 668,260 157.2
Iowa 4.2 6.3 320,838 76.0
Kansas 3.9 6.2 289,571 68.2
Kentucky 4.4 6.2 482,730 116.6
Louisiana 4.2 6.1 483,083 115.9
Maine 4.9 6.2 182,330 44.6
Maryland 4.2 6.2 637,044 152.9
Massachusetts 4.5 6.1 830,786 199.8
Michigan 4.0 6.3 1,080,661 254.9
Minnesota 3.9 6.2 551,638 130.3
Mississippi 4.2 6.2 316,196 75.8
Missouri 4.0 6.3 634,139 149.2
Montana 4.6 6.1 112,746 28.4
Nebraska 3.9 6.2 184,386 43.5
Nevada 3.9 6.0 272,970 68.0
New Hampshire 4.5 6.1 174,862 42.6
New Jersey 4.4 6.1 1,099,225 265.3
New Mexico 4.2 6.1 213,074 52.8
New York 4.4 6.1 2,464,358 591.8
North Carolina 4.2 6.1 1,017,731 244.6
North Dakota 4.2 6.2 68,022 16.1
Ohio 4.0 6.3 1,246,113 293.5




























Oklahoma 4.3 6.1 397,721 96.1
Oregon 4.4 6.1 426,211 106.1
Pennsylvania 4.8 6.1 1,624,511 394.4
Rhode Island 4.6 6.1 134,531 32.4
South Carolina 4.4 6.2 507,582 122.3
South Dakota 4.1 6.3 84,843 20.1
Tennessee 4.4 6.2 702,399 169.5
Texas 3.7 6.1 2,443,337 584.0
Utah 3.2 5.9 239,192 58.2
Vermont 4.7 6.2 85,282 20.8
Virginia 4.2 6.1 865,665 208.1
Washington 4.1 6.1 719,538 178.5
West Virginia 4.9 6.2 217,513 53.1
Wisconsin 4.0 6.2 606,030 143.4
Wyoming 4.2 6.0 59,302 14.9
Median 4.2 6.1 482,730 115.9
*
Analyses adjusted for the following variables: age; age squared; sex; race/ethnicity; education; family income; health insurance status; survey 
year; and indicators variables for cancer, arthritis, asthma, back problems, congestive heart failure, chronic obstructive pulmonary disease, coronary 
heart disease, depression, diabetes, dyslipidemia, HIV/AIDS, hypertension, injuries, other cardiovascular disease, other mental health/substance 
abuse, pneumonia, pregnancies, renal failure, skin disorders, and stroke.
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